While the maintenance of an Overweight rating suggests continued confidence in Milestone Pharmaceuticals' fundamentals and growth prospects, the reduction in the price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially causing minor fluctuations in the stock price. However, the overall positive outlook is likely to support the stock's performance in the near term.